Drug Profile
Research programme: protein kinase inhibitors - Oncodesign/Sanofi
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oncodesign Biotechnology
- Developer Oncodesign Biotechnology; Sanofi
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in France
- 26 Mar 2013 Oncodesign and Sanofi enter into a second agreement to identify kinase inhibitors in the area of tissue protection and repair
- 13 Sep 2012 Early research in Undefined indication in France (unspecified route)